We serve Chemical Name:3-(Dimethoxymethyl)-5-methoxypyridine CAS:1087659-15-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(Dimethoxymethyl)-5-methoxypyridine
CAS.NO:1087659-15-1
Synonyms:a-5921
Molecular Formula:C9H13NO3
Molecular Weight:183.20400
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:40.58000
Exact Mass:183.09000
LogP:1.38160
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like a-5921 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,a-5921 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,a-5921 Use and application,a-5921 technical grade,usp/ep/jp grade.
Related News: As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. 3-(Dimethoxymethyl)-5-methoxypyridine manufacturer As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. 3-(Dimethoxymethyl)-5-methoxypyridine supplier As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. 3-(Dimethoxymethyl)-5-methoxypyridine vendor As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials. 3-(Dimethoxymethyl)-5-methoxypyridine factory The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body.
